参考文献 [1] Gu Hangye, Lü Qing, Chen Yong. Research Progress of Gefitinib in the Treatment of Non-Small Cell Lung Cancer with EGFR Gene Mutation[J]. Chinese Pharmacy, 2023, 34(14): 1788-1792. 编辑:Potato
就在YQ先生确诊2个月前，举世瞩目的FLAURA研究（ III期随机对照临床试验）结果发表在《新英格兰医学杂志》，研究结果显示EGFR 3代靶向药奥希替尼一线治疗晚期NSCLC（non-small cell lung cancer, 非小细胞肺癌）的中位无疾病进展生存期（PFS）长达18.9个月，显著优于1代靶向药[1,2]。因此，YQ先生毫不犹豫地于...
LUNG cancer treatmentDRUG efficacyEPIDERMAL growth factor receptorsPATIENT selectionGENETIC mutationERLOTINIBPROTEIN-tyrosine kinase inhibitorsTHERAPEUTICSTyrosine kinase inhibitors (TKIs) are very efficacious in non-small-cell lung cancer (NSCLC) patients harboring activating Epidermal Growth Facto...
Osimer‐ tinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med,2018,378(2):113-125. [19] CHENG Y,HE Y,LI W,et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC:FLAURA China study overall surviva(...
[14] Yokoyama Y, Sonobe M, Yamada T, et al. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations. Int J Clin Oncol 2015;20:1122...
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nerv...
· 石河子 2013 年5 月 Circulating DNA EGFR mutation and the targeting therapy response in advanced NSCLC patients A Dissertation Submitted to Shihezi University In Partial Fulfillment of the Requirements for the Degree of Master of Medicine By Dissertation Supervisor: May, 2013 石河子大学学位论文独创...
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line[J]. Curr Oncol, 2012, 19(Suppl 1):S52-S58. 3 Zhang L, Yang H, Zhao Y, et al. Detection of EGFR Somatic Muta⁃ tions in Non-Small Cell Lung Cancer (NSCLC) Using a ...
Thoracic oncologists traditionally have made treatment decisions based upon tumor histology, distinguishing non-small cell lung cancer (NSCLC) from small cell lung cancer (SCLC). However, recent data has revealed that at least one histological subtype of NSCLC, lung adenocarcinoma comprises multiple mol...
Impact of EGFR mutation analysis in non-small cell lung cancer The discovery of mutations in the tyrosine kinase domain of the epidermal growth factor receptor ( EGFR) gene in non-small cell lung cancer (NSCLC) acceler... H Yamamoto,S Toyooka,T Mitsudomi - 《Lung Cancer》 被引量: 257发表...